Survival rate

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Retrieved on: 
Tuesday, December 12, 2023
RNA, Metastasis, Survival, Transcoding, TTX, Survival rate, Prognosis, Research, Radiation, Therapy, Cancer, Animal, Neoplasm, Pancreatic cancer, PDAC, Patient, Palliative care, Malignancy, Pharmaceutical industry

The study demonstrated that TTX-MC138 was effective against metastatic (stage IV) pancreatic cancer in animal models.

Key Points: 
  • The study demonstrated that TTX-MC138 was effective against metastatic (stage IV) pancreatic cancer in animal models.
  • There are currently no treatment options for patients with metastatic (stage IV) pancreatic cancer beyond palliative care.
  • The study involved weekly injection of TTX-MC138 into animals bearing human pancreatic tumors.
  • Furthermore, the company believes that these results underscore the efficacy of its TTX platform for the systemic delivery of RNA-based therapeutics into solid tumors.

Giving Tuesday 2023: DCG Giving, a Dave Cantin Group Nonprofit, Donates More Than a Quarter Million Dollars to Boost Pediatric Cancer Research and Treatment Nationwide

Retrieved on: 
Tuesday, November 28, 2023
NADA, National Cancer Institute, Hospital, Hope, University, DCG, Crystal, Acute lymphoblastic leukemia, Survival rate, Research, Children's Hospital Los Angeles, Lymphoid leukemia, Organic, COG, Rutgers University, Cancer, Pharmaceutical industry

“I am grateful to all the benefactors within the automotive industry who supported DCG Giving with their generous donations.

Key Points: 
  • “I am grateful to all the benefactors within the automotive industry who supported DCG Giving with their generous donations.
  • This critical funding for clinical research will help transform the lives of children and young adults,” said Dave Cantin, President and CEO of The Dave Cantin Group.
  • This event focused the automotive industry’s attention on the great need for more childhood cancer research funding.
  • DCG Giving continually supports local pediatric cancer charities from coast to coast.

ESO Releases 2023 ESO Trauma Index to Explore Key Trends and Measures Affecting Trauma Centers Across the Country

Retrieved on: 
Tuesday, December 19, 2023
Data Management, Technology, Professional Services, Managed Care, Health, Law Enforcement, Emergency Services, Data Analytics, Software, Hospitals, Surgery, Public Policy, Government, ESO, Injury, Hospital, Trauma, Cardiac arrest, ED, Risk, Delirium, ISS, Survival rate, Injury Severity Score, Mortality, EMS, SBP, Blood transfusion, Hip, CPR, Emergency medical services, PRBC, BSN, Death, CSTR, Benchmarking, RN, Patient, Intubation, ICU

ESO , the leading data and software company serving hospitals, emergency medical services (EMS), fire departments, state and federal agencies, today announced the findings of its 2023 ESO Trauma Index, a report focused on key trends across hospital trauma programs nationwide.

Key Points: 
  • ESO , the leading data and software company serving hospitals, emergency medical services (EMS), fire departments, state and federal agencies, today announced the findings of its 2023 ESO Trauma Index, a report focused on key trends across hospital trauma programs nationwide.
  • “This year we introduced the penetrating trauma section in response to a national rise in such cases.
  • In doing so, we analyzed patterns in systolic blood pressure (SBP) and Shock Index (SI).
  • The 2023 ESO Trauma Index can be downloaded here.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Retrieved on: 
Wednesday, December 20, 2023
GT0918, Niraparib, Phase, Ipsen, CRPC, Prognosis, Daiichi Sankyo, PSMA, BRCA, FDA, Spacecraft, Gesellschaft mit beschränkter Haftung, DNA, EU4, Cancer, Novartis, ICIS, Abiraterone acetate, Ageing, Urination, PSA, Metastasis, CYP17, Survival rate, Pain, Prevalence, Bristol Myers Squibb, Prednisone, Janssen Pharmaceuticals, Testosterone, PARP, Rucaparib, Urine, Neoplasm, Urethra, Johnson & Johnson, AstraZeneca, Docetaxel, STEAP1, Bone pain, AMG, Blood, ADT, LAS, Patient, Prostate-specific antigen, Astellas Pharma, HRR, Amgen, Prostate cancer, Swelling, Eli Lilly and Company, Hypoesthesia, Science, Growth, Merck & Co., Pressure, Pharmaceutical industry

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.
  • As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM.
  • However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further.
  • The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Hepatology, Cirrhosis, Safety, Randomness, Insulin resistance, Food, TIPS, Incidence, AASLD, Liver, Ascites, Abdomen, Hyponatremia, Patient, Confirmatory trial, Liver transplantation, Control, Survival rate, Inflammation, Liver support system, Terlipressin, Dementia, Standard of care, Acceleration, Orphan, SOC, Poster, Pharmaceutical industry, Medical imaging, Boston

CARSON CITY, Nev., Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced positive clinical safety data from the Company’s Phase 2b open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, with standard of care (SOC) in patients with refractory ascites due to cirrhosis. The data will be highlighted today in a late-breaking poster presentation titled “Safety and Tolerability of Continuous Infusion Terlipressin (BIV201) In Patients with Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study” at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023 in Boston, MA.

Key Points: 
  • The incidence of treatment emergent adverse events (TEAEs), including serious TEAEs, was similar in both treatment groups.
  • Two patients who received BIV201 experienced hyponatremia that developed gradually, was asymptomatic, and was resolved upon discontinuation of the study drug.
  • Primary endpoints were safety and tolerability, and incidence of certain complications (Grade ≥2) during the 180 days following randomization.
  • BIV201, a continuous infusion of terlipressin, received Orphan Drug Designation for treatment of ascites from the U.S. Food and Drug Administration in 2017.

Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association

Retrieved on: 
Saturday, November 11, 2023
Lung, Safety, Hypoplastic left heart syndrome, Food, Rollcage Stage II, Transplant, US Foods, AHA, Mortality, Patient, HLHS, FDA, Survival rate, Trial of the century, American Heart Association, Survival, Growth, SVR, Poster, NHLBI, Pharmaceutical industry

MIAMI, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that extended long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA), being held in Philadelphia, PA on November 11-13, 2023.

Key Points: 
  • The extended follow-up data on all patients enrolled in the study now includes monitoring for up to 5 years following treatment with Lomecel-BTM.
  • The average age at the time of the last follow-up visit was 4.5 years, with 2 patients being 5 years of age.
  • Historical results from outside studies have shown that children with HLHS have approximately 20% mortality by 5 years.
  • The ELPIS I trial ( NCT03525418 ) was an open-label, Phase 1b study designed to evaluate the safety of Lomecel-BTM in patients with HLHS.

Children with cancer evacuated from Gaza for treatment to Egypt and Jordan

Retrieved on: 
Friday, November 10, 2023
World Health Organization, Global Initiative, Rafah Border Crossing, Attack, WHO, Leukemia, History, Patient, Childhood cancer, Uncertainty, Survival rate, Health, Cancer, Region, Hospital, GICC, Physician, Vaccine, Nursing

Additional children are expected to be evacuated for cancer treatment as part of this initiative.

Key Points: 
  • Additional children are expected to be evacuated for cancer treatment as part of this initiative.
  • “I am relieved that children in vital need of cancer care have been able to leave the insecurity and uncertainty in Gaza and continue receiving life-saving treatment in Egypt and Jordan,” said Dr Tedros Adhanom Ghebreyesus, the WHO Director-General.
  • Cancer care services are therefore severely limited, meaning it is critically urgent to transfer patients outside Gaza for treatment.
  • But these children receive only a portion of their cancer care within Gaza due to lack of some cancer services, and, therefore, require referrals to hospitals in the West Bank, including East Jerusalem, Egypt, Israel and Jordan for further treatment.

Romero Britto, Pamela Silva, Maity Interiano, Adrianne Calvo celebrate 20 years of St. Jude Thanks and Giving® campaign at star-studded Miami event

Retrieved on: 
Friday, December 15, 2023
Hispanic, Family, Philanthropy, Oncology, Consumer, Hospitals, Fund Raising, Parenting, Foundation, Children, Other Philanthropy, Health, Holiday, NCI-designated Cancer Center, Hope, National Cancer Institute, Christmas Eve, Love, Food, National Cancer Research Institute, Multimedia, Survival rate, Child, Cancer, Housing, Travel, Hospital, Entertainment, Jude the Apostle

View the full release here: https://www.businesswire.com/news/home/20231215396296/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231215396296/en/
    Pamela Silva, Chef Adrianne Calvo and Maity Interiano (l to r) attend the St. Jude Thanks and Giving Holiday Event at Britto Palace.
  • Guests heard from a St. Jude patient family and enjoyed a delicious feast courtesy of celebrity chef Adrianne Calvo.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

National Beverage Commemorates 30 Years of Supporting ‘HOPE’ for the Children of St. Jude

Retrieved on: 
Friday, December 15, 2023
Children, Health, Philanthropy, Food, Beverage, Oncology, Research, Retail, Hospitals, Fund Raising, Consumer, Science, Survival rate, National Beverage, Child, HOPE, Travel, Housing, Hospital, Jude the Apostle

“The remarkable advancements in research pioneered by St. Jude are responsible for saving countless lives.

Key Points: 
  • “The remarkable advancements in research pioneered by St. Jude are responsible for saving countless lives.
  • At this beautiful holiday season, we ask everyone to please join National Beverage with their generosity for our children.
  • There is no greater joy than providing each and every one of them a future filled with HOPE!” Caporella concluded.
  • Families never receive a bill from St. Jude for treatment, travel, housing or food - so they can focus on helping their child live.